Cargando…

Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation

BACKGROUND: On 8th April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the “preferred” vaccine for adults in Australia aged < 50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlson, Samantha J., McKenzie, Lara, Roberts, Leah, Blyth, Christopher C., Attwell, Katie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674511/
https://www.ncbi.nlm.nih.gov/pubmed/34952758
http://dx.doi.org/10.1016/j.vaccine.2021.12.021
_version_ 1784615681840381952
author Carlson, Samantha J.
McKenzie, Lara
Roberts, Leah
Blyth, Christopher C.
Attwell, Katie
author_facet Carlson, Samantha J.
McKenzie, Lara
Roberts, Leah
Blyth, Christopher C.
Attwell, Katie
author_sort Carlson, Samantha J.
collection PubMed
description BACKGROUND: On 8th April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the “preferred” vaccine for adults in Australia aged < 50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccination. We sought to understand whether this impacted COVID-19 vaccine intentions. METHOD: We undertook qualitative interviews from February – April 2021 before and after the program change with 28 adults in Perth, Western Australia. Using our COVID-19 vaccine intentions model, we assessed changes in participants’ COVID-19 vaccine intention before and after the program change. Participants were classified as 1) ‘acceptors’: no concerns about COVID-19 vaccine safety, efficacy, access and would accept whatever vaccine is offered, 2) ‘cautious acceptors’: some concerns and would prefer a particular vaccine brand but would accept whatever is offered, 3) ‘Wait awhile’: for more data, easier access, for another vaccine brand, a greater perceived COVID-19 threat or until mandatory, or 4) ‘refuser’: no intention to vaccinate due to concerns about safety and/or efficacy. RESULTS: Before the change, 7/18 of those aged < 50 years were ‘acceptors,’ 10/18 were ‘cautious acceptors’ and 1/18 was ‘wait awhile.’ Overall, 14/18 participants had the same COVID-19 vaccine intention after the change; 4/18 became more concerned. For those aged ≥ 50 years and before the change, 5/10 were ‘acceptors’ and 5/10 were ‘cautious acceptors.’ After the change, 8/10 still had the same COVID-19 vaccine intention; 2/10 became more cautious. The major concern before the program change was COVID-19 vaccines having different vaccine efficacy; the concern pivoted to safety. CONCLUSION: The majority of participants were ‘cautious acceptors’ who intended on being vaccinated; many had this intention before and after the program change. The Australian government, health care providers and media need to better address COVID-19 vaccine concerns to assist those with COVID-19 vaccine intentions receive a vaccine.
format Online
Article
Text
id pubmed-8674511
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-86745112021-12-16 Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation Carlson, Samantha J. McKenzie, Lara Roberts, Leah Blyth, Christopher C. Attwell, Katie Vaccine Article BACKGROUND: On 8th April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the “preferred” vaccine for adults in Australia aged < 50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccination. We sought to understand whether this impacted COVID-19 vaccine intentions. METHOD: We undertook qualitative interviews from February – April 2021 before and after the program change with 28 adults in Perth, Western Australia. Using our COVID-19 vaccine intentions model, we assessed changes in participants’ COVID-19 vaccine intention before and after the program change. Participants were classified as 1) ‘acceptors’: no concerns about COVID-19 vaccine safety, efficacy, access and would accept whatever vaccine is offered, 2) ‘cautious acceptors’: some concerns and would prefer a particular vaccine brand but would accept whatever is offered, 3) ‘Wait awhile’: for more data, easier access, for another vaccine brand, a greater perceived COVID-19 threat or until mandatory, or 4) ‘refuser’: no intention to vaccinate due to concerns about safety and/or efficacy. RESULTS: Before the change, 7/18 of those aged < 50 years were ‘acceptors,’ 10/18 were ‘cautious acceptors’ and 1/18 was ‘wait awhile.’ Overall, 14/18 participants had the same COVID-19 vaccine intention after the change; 4/18 became more concerned. For those aged ≥ 50 years and before the change, 5/10 were ‘acceptors’ and 5/10 were ‘cautious acceptors.’ After the change, 8/10 still had the same COVID-19 vaccine intention; 2/10 became more cautious. The major concern before the program change was COVID-19 vaccines having different vaccine efficacy; the concern pivoted to safety. CONCLUSION: The majority of participants were ‘cautious acceptors’ who intended on being vaccinated; many had this intention before and after the program change. The Australian government, health care providers and media need to better address COVID-19 vaccine concerns to assist those with COVID-19 vaccine intentions receive a vaccine. The Authors. Published by Elsevier Ltd. 2022-01-28 2021-12-16 /pmc/articles/PMC8674511/ /pubmed/34952758 http://dx.doi.org/10.1016/j.vaccine.2021.12.021 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Carlson, Samantha J.
McKenzie, Lara
Roberts, Leah
Blyth, Christopher C.
Attwell, Katie
Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation
title Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation
title_full Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation
title_fullStr Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation
title_full_unstemmed Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation
title_short Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation
title_sort does a major change to a covid-19 vaccine program alter vaccine intention? a qualitative investigation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674511/
https://www.ncbi.nlm.nih.gov/pubmed/34952758
http://dx.doi.org/10.1016/j.vaccine.2021.12.021
work_keys_str_mv AT carlsonsamanthaj doesamajorchangetoacovid19vaccineprogramaltervaccineintentionaqualitativeinvestigation
AT mckenzielara doesamajorchangetoacovid19vaccineprogramaltervaccineintentionaqualitativeinvestigation
AT robertsleah doesamajorchangetoacovid19vaccineprogramaltervaccineintentionaqualitativeinvestigation
AT blythchristopherc doesamajorchangetoacovid19vaccineprogramaltervaccineintentionaqualitativeinvestigation
AT attwellkatie doesamajorchangetoacovid19vaccineprogramaltervaccineintentionaqualitativeinvestigation